resTORbio, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2016-01-01
- Employees
- 1
- Market Cap
- -
- Website
- https://www.restorbio.com
Clinical Trials
11
Active:5
Completed:3
Trial Phases
3 Phases
Phase 1:4
Phase 2:5
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Phase 2
5 (45.5%)Phase 1
4 (36.4%)Phase 3
2 (18.2%)A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- Restorbio Inc.
- Target Recruit Count
- 1024
- Registration Number
- NCT04668352
- Locations
- 🇳🇿
P3 Research Ltd., Wellington, New Zealand
A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- Restorbio Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04584710
- Locations
- 🇺🇸
University of Connecticut, UConn Center on Aging, Farmington, Connecticut, United States
🇺🇸Hebrew Senior Life, Marcus Institute for Aging Research, Roslindale, Massachusetts, United States
Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2021-02-10
- Lead Sponsor
- Restorbio Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04409327
- Locations
- 🇺🇸
Nursing Home, Middletown, Rhode Island, United States
Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly
Phase 3
Withdrawn
- Conditions
- Clinically Symptomatic Respiratory Illness
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Restorbio Inc.
- Registration Number
- NCT04139915
Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly
Phase 2
Active, not recruiting
- Conditions
- Respiratory Tract Infections
- Interventions
- First Posted Date
- 2017-12-14
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- Restorbio Inc.
- Target Recruit Count
- 652
- Registration Number
- NCT03373903
- Locations
- 🇺🇸
Heartland Research Associates, Wichita, Kansas, United States
News
No news found